返回
Prelude Therapeutics Inc（PRLD）价格
PRLD 股价走势图
PRLD 收益
Prelude Therapeutics Inc
$1.81
-15.81%
$-0.33
收盘价：Jan 16, 16:00:00 GMT-5
$1.79
-1.1%
$-0.02
盘后：Jan 16, 20:00:00 GMT-5
关键数据
前收盘价
$2.15
开盘价
$2.1
当日区间
$1.78 - $2.1
52周范围
$0.6101 - $4.22
交易量
1.4M
平均成交量
1.1M
每股收益（TTM）
-0.64
股息收益率
--
市值
$112.5M
什么是 PRLD？
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 131 full-time employees. The company went IPO on 2020-09-25. The company has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.